Organon & Co. (NYSE:OGN) Given “Neutral” Rating at BNP Paribas Exane

Organon & Co. (NYSE:OGN)‘s stock had its “neutral” rating reaffirmed by research analysts at BNP Paribas Exane in a research note issued on Wednesday,Benzinga reports. They presently have a $14.00 target price on the stock, up from their previous target price of $12.00. BNP Paribas Exane’s target price would indicate a potential upside of 4.96% from the company’s previous close.

Several other equities research analysts also recently commented on OGN. Wall Street Zen downgraded shares of Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Zacks Research upgraded shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Barclays boosted their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research note on Tuesday, February 24th. Finally, Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their target price for the company from $5.00 to $14.00 in a research note on Tuesday. Four investment analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Stock Performance

Organon & Co. stock traded up $0.02 on Wednesday, hitting $13.34. The company’s stock had a trading volume of 17,209,190 shares, compared to its average volume of 8,118,221. The firm has a market cap of $3.50 billion, a P/E ratio of 18.79, a price-to-earnings-growth ratio of 1.22 and a beta of 0.67. The company has a quick ratio of 1.23, a current ratio of 1.82 and a debt-to-equity ratio of 11.47. The company has a fifty day moving average price of $7.45 and a 200-day moving average price of $7.68. Organon & Co. has a one year low of $5.69 and a one year high of $13.38.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The business had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.52 billion. During the same period last year, the firm earned $0.90 EPS. The company’s quarterly revenue was down 5.3% compared to the same quarter last year. On average, equities analysts anticipate that Organon & Co. will post 3.23 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its position in Organon & Co. by 105.2% during the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after purchasing an additional 4,394,814 shares during the period. Vanguard Group Inc. increased its stake in shares of Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock valued at $383,715,000 after acquiring an additional 3,650,860 shares during the last quarter. UBS Group AG increased its stake in shares of Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after acquiring an additional 1,527,492 shares during the last quarter. Private Management Group Inc. increased its stake in shares of Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after acquiring an additional 1,204,979 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its stake in Organon & Co. by 102.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock worth $23,925,000 after purchasing an additional 1,131,941 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.